Skip to content
PeptideHormone

BPC-157

A synthetic peptide with broad preclinical repair claims and little human data.

Research peptidePreclinical

Drawn from a gastric protein, with a striking preclinical record and almost no human data — the widest gap between interest and evidence in this catalog.

Identity

Class
Synthetic pentadecapeptide (15 aa)
Source
Synthetic; sequence derived from a gastric protein
Receptor
No established receptor; proposed effects on angiogenesis and growth-factor pathways

Key properties

Evidence floorCommunityREF1COMM1
Molecular weight
~1,419.5 Da
REF
Half-life (native)
Poorly characterized in humans
COMMHalf-life is poorly characterized in humans. The figure is indicative of order-of-magnitude, not an established value.

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

BPC-157 is a stable synthetic peptide whose sequence comes from a fragment of a gastric protein. Animal studies report effects on angiogenesis, tendon and gut healing, and nitric-oxide pathways, but its mechanism is not well defined and rigorous human clinical evidence is largely absent.

Reference notes

  • The evidence base is predominantly preclinical (rodent); robust human trials are lacking.
  • Its molecular mechanism is proposed rather than firmly established.
  • It is widely marketed in the 'research peptide' space — a context where claims often outrun data.

Common questions

What is BPC-157?
A synthetic peptide with broad preclinical repair claims and little human data. Structurally it is Synthetic pentadecapeptide (15 aa).
How does BPC-157 work?
BPC-157 is a stable synthetic peptide whose sequence comes from a fragment of a gastric protein. Animal studies report effects on angiogenesis, tendon and gut healing, and nitric-oxide pathways, but its mechanism is not well defined and rigorous human clinical evidence is largely absent.
How strong is the evidence for BPC-157?
PeptideHormone grades BPC-157 at the "Preclinical" evidence tier — the evidence is largely animal or in-vitro, with human data thin or absent. It is catalogued as a community research peptide outside the approved-drug system, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of BPC-157?
The reported circulating half-life of BPC-157 is Poorly characterized in humans.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

  1. 1.Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review · Pharmaceuticals (Basel, Switzerland), 2025 · PMID 40005999
  2. 2.Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing · Cell and tissue research, 2019 · PMID 30915550

External references

BPC-157 in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.